Browsing Tag
Trevi Therapeutics
3 posts
Trevi Therapeutics (NASDAQ: TRVI) bets everything on two Phase 3 chronic cough trials
Trevi Therapeutics (NASDAQ: TRVI) has no revenue and is up 71%, yet its future rides on two Phase 3 cough trials that do not read out until 2027.
Trevi Therapeutics announces positive results for Haduvio in Phase 2b CORAL study
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, has reported a positive outcome from the planned sample size re-estimation…
Trevi Therapeutics reports promising results for Oral Nalbuphine in human abuse potential study
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced positive oral nalbuphine results from its human abuse potential (HAP)…